Clinical trials: Methicillin Susceptible Staphylococcus Aureus Septicemia
Methicillin Susceptible Staphylococcus Aureus Septicemia
Efficacy of Cloxacillin and Fosfomycin Combination Versus Cloxacillin Monotherapy in Patients With MSSA Bacteremia
Background: Despite management improvement in lasts years, S.aureus bacteremia leads to high morbidity and mortality. For over 50 years, methicillin-susceptible S.aureus (MSSA) bacteremia standard treatment was cloxacillin.
- Trial name
- SAFO (NCT03959345)
- Testing
- Combination therapy group, Standard therapy group
- Where
- 17 sites in Spain
- Volunteers
- 215 people
- Sponsor
- Miquel Pujol
Staphylococcus Aureus Infection
Probability of Target Attainment With Standard Intermittent Bolus Administration of Cefazolin in Patients With Complicated Infections Caused by Staphylococcus Aureus
Given the paucity of pharmacological data on cefazolin treatment of Methicillin-susceptible S. aureus (MSSA) complicated S. aureus infection (CSAI), the primary purpose of this study is to investigate the probability of…
- Trial name
- TARGET II (NCT04503252)
- Testing
- Blood samples for the measurement of the concentration of cefazolin, S. aureus culture isolate, structured telephone interview
- Where
- Switzerland
- Volunteers
- 50 people
- Sponsor
- University Hospital, Basel, Switzerland
Methicillin Susceptible Staphylococcus Aureus Septicemia, Bacteremia
Daptomycin as Adjunctive Therapy for Staphylococcus Aureus Bacteremia
The purpose of our study is to examine the effects of a second antibiotic, daptomycin, in combination with a beta lactam antibiotic on treating bloodstream infection caused by methicillin-susceptible S. aureus.
- Trial name
- DASH (NCT02972983)
- Testing
- Daptomycin
- Where
- Canada
- Volunteers
- 102 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Staphylococcus Aureus Bloodstream Infections (BSI; Bacteremia)
Linezolid Plus Standard of Care
The aim of the study is to assess whether targeting virulence factors by administering linezolid in addition to standard antibiotic treatment improves outcomes in patients with Staphylococcus aureus bacteraemia.
- Trial name
- LIPS (NCT06958835)
- Testing
- Linezolid 600 mg
- Where
- 12 sites in Switzerland
- Volunteers
- 606 people
- Sponsor
- University Hospital, Basel, Switzerland
Bacteriemia, Methicillin Susceptible Staphylococcus Aureus (MSSA) Infection
Cefazolin Versus Antistaphylococcal Penicillins for Methicillin Susceptible Staphylococcus Aureus Bacteremia
Background Methicillin-susceptible Staphylococcus aureus (MSSA) bacteraemia is a common and serious infection, associated with significant morbidity and high mortality rates.
- Trial name
- TriPasCef (NCT07186894)
- Testing
- Antistaphylococcal penicillins, Cefazolin
- Volunteers
- 5,000 people
- Sponsor
- Central Hospital, Nancy, France
Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Septicemia
Combination Cefazolin With Ertapenem for Methicillin-susceptible Staphylococcus Aureus Bacteremia
There is a variety of in vitro, in vivo (animal model), and human case series data which suggests that the addition of ertapenem to cefazolin could improve outcomes in methicillin-susceptible S. aureus bacteremia.
- Conditions
- Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Septicemia, Staphylococcal Sepsis, Staphylococcus Aureus Endocarditis
- Trial name
- CERT (NCT04886284)
- Testing
- Ertapenem
- Where
- 7 sites in Canada
- Volunteers
- 60 people
- Sponsor
- Todd C. Lee MD MPH FIDSA
Bacteremia Due to Methicillin Susceptible Staphylococcus Aureus
Non-inferiority Trial Comparing Cloxacillin vs Cefazolin in Methicillin-susceptible Staphylococcus Aureus Bacteremia
"Methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia remains a major cause of community- or hospital-acquired bloodstream infections with an overall mortality estimated around 25%.
- Trial name
- CLOCEBA (NCT03248063)
- Testing
- Cloxacillin, Cefazolin
- Where
- France
- Volunteers
- 315 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris